Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biktarvy vs Symtuza in Advanced HIV Disease
NCT03696160Phase 3Completed
- Sponsor
- NEAT ID Foundation
- Start
- Mar 2019
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by NEAT ID Foundation. Primary endpoint: Treatment Failure at 48 weeks. Started Mar 2019; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03696160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03696160.